Laguna and Neurocrine advance schizophrenia diagnostic and treatment programs
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
NBI-1117570
DrugRelated News
Neurocrine doses first patients in Phase 2 schizophrenia trial of NBI-1117570
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.